Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
11(46%)
Results Posted
57%(4 trials)
Terminated
3(13%)

Phase Distribution

Ph phase_2
13
54%
Ph not_applicable
2
8%
Ph phase_1
7
29%
Ph phase_3
2
8%

Phase Distribution

7

Early Stage

13

Mid Stage

2

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
7(29.2%)
Phase 2Efficacy & side effects
13(54.2%)
Phase 3Large-scale testing
2(8.3%)
N/ANon-phased studies
2(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

11

trials recruiting

Total Trials

24

all time

Status Distribution
Active(11)
Completed(7)
Terminated(4)
Other(2)

Detailed Status

Recruiting8
Completed7
Terminated3
Active, not recruiting3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
11
Success Rate
70.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (29.2%)
Phase 213 (54.2%)
Phase 32 (8.3%)
N/A2 (8.3%)

Trials by Status

terminated313%
unknown28%
active_not_recruiting313%
withdrawn14%
recruiting833%
completed729%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT07219212Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT01512589Phase 2

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Active Not Recruiting
NCT03953976Phase 2

INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy

Completed
NCT06470282Phase 1

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
NCT04774419Phase 2

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Recruiting
NCT04165772Phase 2

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting
NCT06331468Phase 2

Hypofractionated Radiochemotherapy

Recruiting
NCT05301283Phase 2

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Recruiting
NCT06867484Not Applicable

Breast Re-irradiation After Second Ipsilateral Lumpectomy

Recruiting
NCT02474368Phase 1

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Active Not Recruiting
NCT01420250Phase 1

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Completed
NCT02710734Phase 2

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Active Not Recruiting
NCT05966194Phase 2

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Recruiting
NCT01985828Not Applicable

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Completed
NCT03840902Phase 2

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Terminated
NCT01554410Phase 1

Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

Completed
NCT03536182Phase 3

Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Withdrawn
NCT02537223Phase 1

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Completed
NCT03932266Phase 2

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Unknown
NCT03051906Phase 1

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer

Unknown

Drug Details

Intervention Type
RADIATION
Total Trials
24